STOCK TITAN

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

Rhea-AI Impact
(No impact)
Rhea-AI Sentiment
(Negative)
Tags

Emergent BioSolutions (NYSE:EBS) has partnered with Voices for Awareness and Facing Fentanyl Now to support National Fentanyl Prevention and Awareness Day™ on August 21, 2025. The initiative includes high-visibility billboards in Times Square, NYC to raise awareness about fentanyl risks and reduce stigma around opioid poisonings.

The campaign highlights that synthetic opioids like fentanyl contribute to nearly 70% of all overdose deaths. Through its Ready to Rescue initiative, Emergent is focusing on public education and expanding access to naloxone products, including over-the-counter NARCAN® Nasal Spray 4 mg and prescription KLOXXADO® Nasal Spray 8 mg.

Emergent BioSolutions (NYSE:EBS) ha collaborato con Voices for Awareness e Facing Fentanyl Now per sostenere la Giornata Nazionale per la Prevenzione e Sensibilizzazione sul Fentanil™ del 21 agosto 2025. L'iniziativa prevede cartelloni ad alta visibilità a Times Square, New York, per informare sui rischi del fentanil e ridurre lo stigma legato alle intossicazioni da oppioidi.

La campagna sottolinea che gli oppioidi sintetici come il fentanil sono responsabili di . Attraverso l'iniziativa Ready to Rescue, Emergent si concentra sull'educazione pubblica e sull'ampliamento dell'accesso ai prodotti a base di naloxone, inclusi il farmaco da banco NARCAN® Nasal Spray 4 mg e il prescrivibile KLOXXADO® Nasal Spray 8 mg.

Emergent BioSolutions (NYSE:EBS) se ha unido a Voices for Awareness y Facing Fentanyl Now para apoyar el Día Nacional de Prevención y Concienciación sobre el Fentanilo™ el 21 de agosto de 2025. La iniciativa incluye vallas publicitarias de gran visibilidad en Times Square, Nueva York, para aumentar la concienciación sobre los riesgos del fentanilo y reducir el estigma asociado a las intoxicaciones por opioides.

La campaña destaca que los opioides sintéticos como el fentanilo contribuyen a casi el 70% de todas las muertes por sobredosis. A través de su iniciativa Ready to Rescue, Emergent se centra en la educación pública y en ampliar el acceso a productos con naloxona, incluidos el de venta libre NARCAN® Nasal Spray 4 mg y el con receta KLOXXADO® Nasal Spray 8 mg.

Emergent BioSolutions (NYSE:EBS)는 Voices for Awareness 및 Facing Fentanyl Now와 협력하여 2025년 8월 21일 개최되는 국가 펜타닐 예방 및 인식의 날™을 지원합니다. 이 캠페인은 뉴욕 타임스스퀘어의 고가시성 빌보드를 통해 펜타닐 위험성에 대한 인식을 높이고 아편유사제 중독에 대한 낙인을 줄이는 것을 목표로 합니다.

캠페인은 펜타닐과 같은 합성 오피오이드가 전체 과다복용 사망의 거의 70%에 기여하고 있음을 강조합니다. Emergent는 Ready to Rescue 이니셔티브를 통해 공중 교육을 강화하고 OTC 제품인 NARCAN® Nasal Spray 4 mg와 처방약인 KLOXXADO® Nasal Spray 8 mg을 포함한 날록손 제품 접근을 확대하는 데 주력하고 있습니다.

Emergent BioSolutions (NYSE:EBS) s'est associé à Voices for Awareness et Facing Fentanyl Now pour soutenir la Journée nationale de prévention et de sensibilisation au fentanyl™ le 21 août 2025. L'initiative comprend des panneaux d'affichage très visibles à Times Square, New York, afin de sensibiliser aux risques liés au fentanyl et de réduire la stigmatisation autour des intoxications aux opioïdes.

La campagne souligne que les opioïdes synthétiques comme le fentanyl sont responsables de près de 70 % de tous les décès par surdose. Dans le cadre de son initiative Ready to Rescue, Emergent met l'accent sur l'éducation du public et l'élargissement de l'accès aux produits à base de naloxone, y compris le NARCAN® Nasal Spray 4 mg en vente libre et le KLOXXADO® Nasal Spray 8 mg sur ordonnance.

Emergent BioSolutions (NYSE:EBS) hat sich mit Voices for Awareness und Facing Fentanyl Now zusammengeschlossen, um den Nationalen Tag zur Prävention und Bewusstseinsbildung über Fentanyl™ am 21. August 2025 zu unterstützen. Die Initiative umfasst gut sichtbare Werbetafeln am Times Square in New York, um auf die Risiken von Fentanyl hinzuweisen und das Stigma bei Opioidvergiftungen zu verringern.

Die Kampagne macht deutlich, dass synthetische Opioide wie Fentanyl zu fast 70 % aller Überdosis-Todesfälle beitragen. Im Rahmen der Initiative Ready to Rescue konzentriert sich Emergent auf Aufklärung der Öffentlichkeit und die Ausweitung des Zugangs zu Naloxon-Produkten, einschließlich des rezeptfreien NARCAN® Nasal Spray 4 mg und des verschreibungspflichtigen KLOXXADO® Nasal Spray 8 mg.

Positive
  • None.
Negative
  • None.

GAITHERSBURG, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- As opioid emergencies continue to be the leading cause of accidental death in the United States,1 Emergent BioSolutions (NYSE: EBS) is teaming up with Voices for Awareness and Facing Fentanyl Now in honor of National Fentanyl Prevention and Awareness Day™ on August 21, 2025. As part of this year’s efforts, these leading advocacy organizations and its sponsors will bring their message to Times Square, NYC on the day with several high-visibility billboards that expose fentanyl risks and urge a nationwide call to action to reduce the stigma around opioid poisonings ensuring that more people can be prepared to save a life. Synthetic opioids, such as fentanyl, are a key driver of the opioid epidemic, contributing to nearly 70 percent of all overdose deaths.2 Its undetectable nature—lacking taste, smell, or visible characteristics—makes fentanyl particularly dangerous, and this partnership underscores a shared commitment to saving lives through increased public awareness.

National Fentanyl Prevention and Awareness Day™, observed nationwide and recognized by the U.S. Senate, serves as a critical platform to bring together families, community leaders, law enforcement, and federal agencies to combat the devastating impact of the fentanyl crisis. In memory of the countless lives lost to opioid poisonings, the day focuses on distributing life-saving naloxone, sharing vital opioid overdose prevention education and amplifying messages designed to protect communities from illicit fentanyl.

“We’re proud to sponsor Voices for Awareness and Facing Fentanyl Now on National Fentanyl Prevention and Awareness Day™ to help provide much-needed awareness about fentanyl risks and life-saving tools like naloxone nasal spray,” states Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “Sadly, we are still losing far too many lives each day from opioid overdoses – this includes counterfeit pills that contain deadly fentanyl – so we must continue to educate the public on the signs of an opioid emergency and the importance of carrying naloxone.”

In light of the large number of opioid overdose fatalities in recent years,3 Emergent has remained committed to educating the public through its Ready to Rescue initiative. The campaign is focused on combating misinformation surrounding opioid poisonings and empowering the public to make the socially responsible decision to carry over-the-counter naloxone because opioid emergencies can happen to anyone, anywhere, at any time. Emergent will continue to identify pathways to expand access to multiple forms of naloxone, including over-the-counter NARCAN® Nasal Spray 4 mg and prescription KLOXXADO® Nasal Spray 8 mg to help ensure that every state, business, university and household is prepared to save a life.

For more information about National Fentanyl Prevention and Awareness Day™ and how to get involved, visit FacingFentanylNow.com or VoicesforAwareness.com. To learn how to be prepared in an opioid emergency with life-saving intranasal naloxone, visit NARCAN.com or KLOXXADO.com.

About NARCAN® Nasal Spray
NARCAN® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN® Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed.

Important Safety Information for KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
What is KLOXXADO® Nasal Spray?

  • KLOXXADO® Nasal Spray is a prescription medicine used for the treatment of an opioid emergency such as an overdose or a possible opioid overdose in adults and children with signs of breathing problems and severe sleepiness or not being able to respond.
  • KLOXXADO® Nasal Spray is to be given right away and does not take the place of emergency medical care.
  • Get emergency medical help right away after giving the first dose of KLOXXADO® Nasal Spray, even if the person wakes up.

What is the most important information I should know about KLOXXADO® Nasal Spray?
Get emergency medical help right away after giving the first dose of KLOXXADO® Nasal Spray. The signs and symptoms of an opioid emergency can return after KLOXXADO® Nasal Spray is given. If this happens, give another dose after 2 to 3 minutes using a new KLOXXADO® Nasal Spray and watch the person closely until emergency help is received.

The medicine in KLOXXADO® Nasal Spray is safe to use in people who are not taking opioids. KLOXXADO® Nasal Spray is not intended for self-administration.

What should I tell my healthcare provider (pharmacist or prescriber) before using KLOXXADO® Nasal Spray?
Before using KLOXXADO® Nasal Spray, tell your healthcare provider about all of your medical conditions, including if you:

  • have heart problems
  • are pregnant or plan to become pregnant. Use of KLOXXADO® Nasal Spray may cause withdrawal symptoms in your unborn baby. Your unborn baby should be examined by a healthcare provider right away after you use KLOXXADO® Nasal Spray.
  • are breastfeeding or plan to breastfeed. It is not known if KLOXXADO® Nasal Spray passes into your breast milk.

What are the possible side effects of KLOXXADO® Nasal Spray?
KLOXXADO® Nasal Spray may cause severe opioid withdrawal symptoms including body aches, diarrhea, increased heart rate, fever, runny nose, sneezing, goose bumps, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, stomach cramping, weakness, and increased blood pressure.

In infants under 4 weeks old who have been receiving opioids regularly, sudden opioid withdrawal may be life-threatening if not treated the right way. Signs and symptoms include seizures, crying more than usual, and increased reflexes.

Who should not use KLOXXADO® Nasal Spray?
Do not use KLOXXADO® Nasal Spray if you are allergic to naloxone hydrochloride or any of the ingredients in KLOXXADO® Nasal Spray.

What are the most common side effects of KLOXXADO® nasal spray?
The most common side effects of KLOXXADO® Nasal Spray in adults include stomach-area (abdomen) pain, weakness, dizziness, headache, nose (nasal) discomfort, and a feeling like you are going to faint.

These are not all of the possible side effects of KLOXXADO® Nasal Spray. Please see full Prescribing Information, including Patient Information, which includes a more complete discussion of the risks associated with KLOXXADO® Nasal Spray. Always contact your healthcare provider (pharmacist or prescriber) if you have questions or experience any side effects.

You are encouraged to report negative side effects to the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch. You can also contact Hikma Specialty USA Inc. at: us.hikma@primevigilance.com or call 1-877-845-0689 or 1-800-962-8364.

Trademarks and logos are the property of their respective owners.

About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

___________________
1
https://injuryfacts.nsc.org/all-injuries/preventable-death-overview/odds-of-dying/
2 https://www.cdc.gov/stop-overdose/caring/fentanyl-facts.html
3 https://www.kff.org/mental-health/issue-brief/opioid-deaths-fell-in-mid-2023-but-progress-is-uneven-and-future-trends-are-uncertain/


FAQ

What is Emergent BioSolutions (EBS) doing for National Fentanyl Prevention and Awareness Day 2025?

EBS is partnering with Voices for Awareness and Facing Fentanyl Now, featuring awareness campaigns in Times Square and promoting education about naloxone use for opioid emergencies.

What products does Emergent BioSolutions offer for opioid overdose prevention?

Emergent offers NARCAN® Nasal Spray 4 mg (over-the-counter) and KLOXXADO® Nasal Spray 8 mg (prescription) naloxone products.

How significant is fentanyl in current overdose deaths according to EBS?

According to the announcement, synthetic opioids like fentanyl contribute to nearly 70% of all overdose deaths.

Where can I learn more about Emergent BioSolutions' opioid emergency preparedness programs?

Information is available at NARCAN.com or KLOXXADO.com, as well as through the Ready to Rescue initiative.
Emergent Biosolutions Inc

NYSE:EBS

EBS Rankings

EBS Latest News

EBS Latest SEC Filings

EBS Stock Data

483.89M
51.71M
2.86%
70.01%
18.65%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
GAITHERSBURG